发明名称 |
LKB1 AS PREDICTIVE MARKER OF EVEROLIMUS EFFICACY IN BREAST CANCER |
摘要 |
Method for identifying a breast cancer likely to respond to treatment with everolimus comprising the following steps: Measuring the level of expression of the LKB 1 gene in a breast tumour sample previously taken from a breast cancer patient, Classifying the breast cancer as likely to respond to treatment with everolimus if the LKB1 gene is under-expressed in said breast tumour sample. |
申请公布号 |
US2015250770(A1) |
申请公布日期 |
2015.09.10 |
申请号 |
US201314411291 |
申请日期 |
2013.07.01 |
申请人 |
CENTRE LEON BERARD ;INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM) ;UNIVERSITE CLAUDE BERNARD LYON 1 |
发明人 |
Treilleux Isabelle;Bachelot Thomas;Le Romancer-Cherifi Muriel |
分类号 |
A61K31/436;A61K31/138;G01N33/574 |
主分类号 |
A61K31/436 |
代理机构 |
|
代理人 |
|
主权项 |
|
地址 |
Lyon FR |